Clinical translation of therapeutic
peptides, particularly those targeting intracellular
protein-
protein interactions (PPIs), has been hampered by their inefficacious cellular internalization in diseased tissue. Therapeutic
peptides engineered into nanostructures with stable spatial architectures and smart disease targeting ability may provide a viable strategy to overcome the
pharmaceutical obstacles of
peptides. This study describes a strategy to assemble therapeutic
peptides into a stable
peptide-Au nanohybrid, followed by further self-assembling into higher-order nanoclusters with responsiveness to tumor microenvironment. As a proof of concept, an anticancer
peptide termed β-
catenin/Bcl9 inhibitors is copolymerized with
gold ion and assembled into a cluster of nanohybrids (pCluster). Through a battery of in vitro and in vivo tests, it is demonstrated that pClusters potently inhibit
tumor growth and
metastasis in several animal models through the impairment of the Wnt/β-
catenin pathway, while maintaining a highly favorable biosafety profile. In addition, it is also found that pClusters synergize with the PD1/PD-L1 checkpoint blockade
immunotherapy. This new strategy of
peptide delivery will likely have a broad impact on the development of
peptide-derived therapeutic nanomedicine and reinvigorate efforts to discover
peptide drugs that target intracellular PPIs in a great variety of human diseases, including
cancer.